» Articles » PMID: 19130464

Pancreatic Neuroendocrine Tumors: the Impact of Surgical Resection on Survival

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2009 Jan 9
PMID 19130464
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although surgical resection is generally recommended for patients with localized pancreatic neuroendocrine tumors (PNETs), the impact of resection on overall survival is unknown. The authors investigated the survival advantage of pancreatic resection using a national database.

Methods: This is a retrospective survival analysis of patients with PNETs from the Surveillance, Epidemiology, and End Results database (1988-2002).

Results: A total of 728 patients with PNETs were identified with a median survival of 43 months using Kaplan-Meier survival methods. Resection of tumor was associated with significantly improved survival compared with those patients who were recommended for but did not undergo resection (114 months vs 35 months; P < .0001). This survival benefit was demonstrated for patients with localized, regional, and metastatic disease. A multivariable Cox proportional hazards model was constructed to assess the overall effect of surgical resection on survival, and demonstrated an adjusted odds ratio of 0.48 (95% confidence interval, 0.35-0.66) compared with those who were recommended for surgery but did not proceed to surgery.

Conclusions: The authors have demonstrated in a large national study that resection of primary tumor in patients with PNETs is associated with improved survival across all disease stages. Patients with localized, regional, and metastatic PNETs who are reasonable operative candidates should be considered for resection of their primary tumors.

Citing Articles

Evaluation of the details and importance of lymphatic, microvascular, and perineural invasion in patients with non-functioning pancreatic neuroendocrine neoplasms based on tumor size and the 2022 World Health Organization classification: a 23-year....

Izumo W, Kawaida H, Saito R, Nakata Y, Amemiya H, Maruyama S World J Surg Oncol. 2025; 23(1):79.

PMID: 40055716 PMC: 11889744. DOI: 10.1186/s12957-025-03734-0.


The importance of microvascular invasion in patients with non-functioning pancreatic neuroendocrine neoplasm.

Izumo W, Higuchi R, Furukawa T, Shiihara M, Uemura S, Yazawa T Langenbecks Arch Surg. 2024; 410(1):8.

PMID: 39676094 DOI: 10.1007/s00423-024-03563-x.


Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide.

Gao H, Zhang W, Li Z, Liu W, Liu M, Zhuo Q BMC Cancer. 2024; 24(1):1362.

PMID: 39511555 PMC: 11542389. DOI: 10.1186/s12885-024-13117-5.


Prospective study on stereotactic body radiotherapy for small pancreatic neuroendocrine tumors: tolerance and effectiveness analysis.

Lopez Gonzalez M, Hernando-Requejo O, Ciervide Jurio R, Montero Luis A, Saiz Guisasola C, Sanchez Saugar E Clin Transl Oncol. 2024; 27(1):377-385.

PMID: 38907097 DOI: 10.1007/s12094-024-03538-w.


Prediction of the lymphatic, microvascular, and perineural invasion of pancreatic neuroendocrine tumors using preoperative magnetic resonance imaging.

Liu Y, Zhu H, Chen M, Sun W, Li X, Sun Y World J Gastrointest Surg. 2024; 15(12):2809-2819.

PMID: 38222000 PMC: 10784819. DOI: 10.4240/wjgs.v15.i12.2809.